

Titolo:	A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Patologia:	neutropenia congenita o neutropenia cronica autoimmune
Tipo di Studio:	interventistico randomizzato
Fase:	Fase III randomizzato
Principali criteri di inclusione:	Diagnosis of congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorder ≥ 6 months prior to the screening visit that is not attributable to medications, active or recent infections or malignancy. Congenital Neutropenia, including but not limited to these classifications: Isolated with a permanent (non-cyclic) presentation, for example, elastase, neutrophil expressed (ELANE), colony stimulating factor 3 receptor (CSF3R), C-X-C chemokine receptor 2 (CXCR2), Wiskott-Aldrich syndrome (WAS) Associated with extra-hematologic manifestations, for example, Barth syndrome, Cohen syndrome, glucose-6-phosphatase catalytic subunit 3 (G6PC3), Kostmann disease Associated with metabolic disorders, for example, glycogen storage disease 1b (GSD1b) Shwachman-Diamond syndrome
Principali criteri di esclusione:	A diagnosis of secondary neutropenia including those due to: Hypersplenism Infection Malignancy Autoimmune disease, for example, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, graft-versus-host disease, thyroid disease Nutritional deficiency, for example, vitamin B12, folic acid, copper, caloric malnutrition Drug-induced cause, for example, chemotherapy, clozapine, antiretrovirals, antibiotics, monoclonal antibodies.

	A diagnosis of Aplastic anemia Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome
Sede e contatti	SC Ematologia Dott.sa Chiara Frairia cfrairia@cittadellasalute.to.it